HC Wainwright set a $11.00 price objective on Soligenix Inc. (NASDAQ:SNGX) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Separately, Maxim Group increased their price target on shares of Soligenix from $4.00 to $5.00 and gave the company a buy rating in a research report on Monday.

Soligenix (NASDAQ SNGX) opened at 2.18 on Monday. The company has a 50-day moving average of $2.27 and a 200-day moving average of $2.44. Soligenix has a 52-week low of $2.17 and a 52-week high of $14.40. The company’s market cap is $12.36 million.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Friday, August 11th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.09. Soligenix had a negative net margin of 86.15% and a negative return on equity of 129.88%. The business had revenue of $1 million for the quarter, compared to the consensus estimate of $1.43 million. On average, equities research analysts expect that Soligenix will post ($1.40) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Soligenix Inc. (SNGX) Given a $11.00 Price Target by HC Wainwright Analysts” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/17/soligenix-inc-sngx-given-a-11-00-price-target-by-hc-wainwright-analysts.html.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Stock Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related stocks with our FREE daily email newsletter.